These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 17631180)

  • 1. Risks and benefits of erythropoiesis-stimulating agents in cancer management.
    Beutel G; Ganser A
    Semin Hematol; 2007 Jul; 44(3):157-65. PubMed ID: 17631180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR; Dunst J; Vaupel P
    Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin in cancer-related anemia.
    Fenner MH; Ganser A
    Curr Opin Oncol; 2008 Nov; 20(6):685-9. PubMed ID: 18841051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoiesis-stimulating agents for anemic patients with cancer.
    Sheikh S; Littlewood TJ
    Expert Rev Hematol; 2010 Dec; 3(6):697-704. PubMed ID: 21091146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer-related anemia and recombinant human erythropoietin--an updated overview.
    Bohlius J; Weingart O; Trelle S; Engert A
    Nat Clin Pract Oncol; 2006 Mar; 3(3):152-64. PubMed ID: 16520805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment options for anemia, taking risks into consideration: erythropoiesis-stimulating agents versus transfusions.
    Spano JP; Khayat D
    Oncologist; 2008; 13 Suppl 3():27-32. PubMed ID: 18458122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.
    Spaëth D
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):875-85. PubMed ID: 18533797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
    Aapro MS; Link H
    Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin and chronic lymphocytic leukemia.
    Mauro FR; Gentile M; Foa R
    Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human erythropoietin in the treatment of nonrenal anemia.
    Heuser M; Ganser A
    Ann Hematol; 2006 Feb; 85(2):69-78. PubMed ID: 16078035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
    Pirker R
    Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimising the management of anaemia in patients with cancer with practice guidelines using erythropoiesis-stimulating proteins.
    Smyth D; Zumbrink S
    Eur J Oncol Nurs; 2005; 9 Suppl 1():S3-S13. PubMed ID: 16202653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venous thromboembolic events and erythropoiesis-stimulating agents: an update.
    Dicato M
    Oncologist; 2008; 13 Suppl 3():11-5. PubMed ID: 18458119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.
    Desai J; Demetri GD
    Best Pract Res Clin Haematol; 2005; 18(3):389-406. PubMed ID: 15792913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment.
    Repetto L; Moeremans K; Annemans L;
    Cancer Treat Rev; 2006; 32 Suppl 2():S5-9. PubMed ID: 16725267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications.
    Gascón P
    Oncologist; 2008; 13 Suppl 3():4-10. PubMed ID: 18458118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia.
    Vaupel P; Dunst J; Engert A; Fandrey J; Feyer P; Freund M; Jelkmann W
    Onkologie; 2005 Apr; 28(4):216-21. PubMed ID: 15840971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Summary version of the Standards, Options and Recommendations for the use of recombinant erythropoietin (epoietin-alpha and beta, darbepoietin-alpha, EPO) in the management of anaemia in oncology - Update 2003].
    Spaeth D; Casadevall N; Daouphars M; Marchal C; Marec-Berard P; Fabre N; Haugh M;
    Bull Cancer; 2004 Feb; 91(2):179-88. PubMed ID: 15047458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developments in the therapeutic use of erythropoiesis stimulating agents.
    Jelkmann W
    Br J Haematol; 2008 May; 141(3):287-97. PubMed ID: 18410567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EPO in cancer anemia: benefits and potential risks.
    Milano M; Schneider M
    Crit Rev Oncol Hematol; 2007 May; 62(2):119-25. PubMed ID: 17197190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.